Despite EGFR amplification occurring in 40% of GBM and EGFRvIII mutation in 20%, clinical trials of EGFR tyrosine kinase inhibitors and peptide vaccines (like rindopepimut) in GBM patients have yielded disappointing results.31, 95, 97, 98. The gene discussed is EGFR; the disease is glioblastoma.